CM
IBRX icon

Caption Management’s ImmunityBio IBRX Stock Holding History

Caption Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.7K Buy
10,698
+9,698
+970% +$73.4K ﹤0.01% 1526
2026
Q1 		$7.67K Buy
+1,000
New +$6.85K ﹤0.01% 1468
2025
Q4 		– Sell
-46,300
Closed -$114K – 1807
2025
Q3 		$114K Buy
46,300
+31,300
+209% +$80.6K ﹤0.01% 1521
2025
Q2 		$39.6K Sell
15,000
-10,000
-40% -$26.9K ﹤0.01% 1351
2025
Q1 		$75.3K Buy
+25,000
New +$75.8K ﹤0.01% 1376
2024
Q4 		– Sell
-26,032
Closed -$108K – 1619
2024
Q3 		$96.8K Hold
26,032
– – ﹤0.01% 1134
2024
Q2 		$165K Sell
26,032
-47,622
-65% -$314K ﹤0.01% 978
2024
Q1 		$396K Buy
+73,654
New +$334K 0.01% 913

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caption Management's IBRX Position: Q2 2026 in Review

Caption Management increased its ImmunityBio (IBRX) stake by 970% in Q2 2026, buying an estimated $73.4K and bringing the position to 10,698 shares worth $93.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Caption Management first reported a position in IBRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $396K in Q1 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Caption Management held 10,698 shares of ImmunityBio worth $93.7K as of Q2 2026.
  • Caption Management bought 9,698 ImmunityBio shares in Q2 2026, an estimated $73.4K.
  • ImmunityBio made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1526 holding.
  • Caption Management first reported a position in ImmunityBio in Q1 2024 and has held it in 8 quarters since.
  • Caption Management's ImmunityBio position peaked at $396K in Q1 2024.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.